Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Cancer: Page 4
FDA issues safety warning for risk of T-cell malignancies with CAR T-cell therapies
By
LabPulse.com staff writers
The FDA issued a safety warning that patients who have received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies may be at higher risk of developing new T-cell malignancies, including CAR-positive lymphoma.
November 30, 2023
AI model could prevent unnecessary treatment for breast cancer patients, says study
By
Matt Limb
Breast cancer patients could be spared unnecessary chemotherapy with the use of a new artificial intelligence (AI) tool that helps predict survival risk, say researchers.
November 30, 2023
Candel Therapeutics to lay off 50% of workforce, refocus on advanced oncology immunotherapies
By
LabPulse.com staff writers
Candel Therapeutics, a biopharmaceutical company focused on developing cancer-fighting immunotherapies, will lay off 50% of its workforce.
November 28, 2023
Nanopore sequencing slashes tumor analysis times and costs
By
Nick Paul Taylor
Nanopore sequencing makes the analysis of copy number variations (CNVs) faster, cheaper, and simpler, according to a preprint paper from researchers at Dartmouth-Hitchcock Medical Center.
November 28, 2023
Universal DX partners with Quest Diagnostics, closes $70M series B financing round
By
LabPulse.com staff writers
Liquid biopsy firm Universal DX and Quest Diagnostics have formed a strategic collaboration under which Quest will exclusively offer services for Universal DX’s Signal-C colorectal cancer screening test in the U.S.
November 21, 2023
AnchorDx, DiaCarta to collaborate on cancer diagnostics
By
LabPulse.com staff writers
Biotech company AnchorDx has entered into a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products for the global market.
November 14, 2023
Fragment of C. diff toxin shows preclinical promise as breast cancer treatment
By
Nick Paul Taylor
A fragment of a
Clostridium difficile
toxin could improve outcomes in patients with hard-to-treat forms of breast cancer, according to a paper published in
PLOS Biology
.
November 13, 2023
FDA grants approval to Takeda’s metastatic colorectal cancer therapy
By
LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has approved a chemotherapy-free oral target therapy for patients who have been previously treated for metastatic colorectal cancer (mCRC).
November 9, 2023
Pan-cancer study reveals epigenomic drivers for cancer development, progression
By
LabPulse.com staff writers
A team of researchers have identified epigenomic drivers associated with cancer development and progression, constructing a pan-cancer epigenetic and transcriptomic atlas from the data.
November 3, 2023
Velsera, Solaris Health partner to expand genetic testing access to urology practices
By
LabPulse.com staff writers
Healthcare technology company Velsera and urological services platform Solaris Health are collaborating to expand access to genetic testing to cancer patients and their physicians at urology practices affiliated with Solaris.
November 8, 2023
Illumina unveils new version of liquid biopsy assay
By
Matt Limb
Genomics company Illumina has announced a new generation of its distributed liquid biopsy assay for the genomic profiling of solid tumors.
November 8, 2023
Blood test for biomarker offers route to affordable cancer screening
By
Nick Paul Taylor
Researchers have developed a sensitive blood test for a highly specific biomarker of multiple common tumors, laying the groundwork for a product that could improve cancer screening.
November 6, 2023
Previous Page
Page 4 of 96
Next Page
